

Association of American Cancer Institutes

3708 Fifth Avenue Medical Arts Building, Suite 503 Pittsburgh, PA 15213


Phone: 412-647-6111

www.aaci-cancer.org



ANNUAL MEETING

OCTOBER 25 - 27, 2015



CME provided jointly by the American Association for Cancer Research and the Association of American Cancer Institutes.

Table of Contents

Welcome	1
Program Committee	2
Agenda	3
Continuing Medical Education	11
Awardee Profiles	13
Support	16
Exhibitors	17
Disclosure of Financial Relationships	20

WIRELESS INTERNET AND PRESENTATION INFORMATION

Network: MandarinOriental

Password: AACI

To access the 2015 AACI/CCAF Annual Meeting documents please visit

http://portal.aaci-cancer.org From that page, select: Login

The email login is info@aaci-cancer.org and the password is 2015aaciccaf

Welcome

n behalf of the 2015 AACI/CCAF Annual Meeting Program Committee, welcome to the nation's capital for an exciting and informative meeting!

The cancer centers represented by the Association of American Cancer Institutes (AACI) form North America's cancer research infrastructure and are the hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2015 AACI/CCAF Annual Meeting.

This event convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices. No other program presents information on cancer research and patient care issues as they pertain to the leaders of academic cancer centers, and provides them with a forum to discuss common issues.

This year's meeting includes panel discussions covering a range of issues vital to the cancer research enterprise, including supporting the unique functions of academic cancer centers, understanding and developing immunotherapy programs, improving cancer care through innovative health information technology, and evaluating emerging areas of cancer research. In addition, attendees will hear the latest about AACI initiatives such as "The Academic Difference"—Dr. George Weiner's AACI Presidential Initiative—and AACI's expanding Clinical Research Initiative, along with updates from the National Cancer Institute on its intramural and cancer center programs.

I hope that you and your colleagues find great value in both the content of this year's program and the networking opportunities provided by our annual gathering.

Sincerely, Barbara Duffy Stewart, MPH AACI Executive Director

Program Committee

2015 AACI/CCAF Annual Meeting Program Committee Members

Chair: Patrick J. Loehrer, Sr., MD

Indiana University Melvin and Bren Simon Cancer Center

Michael J. Bertram, PhD, MBA

UAB Comprehensive Cancer Center University of Alabama at Birmingham

Anita L. Harrison, MPH

Hollings Cancer Center Medical University of South Carolina

Candace S. Johnson, PhD

Roswell Park Cancer Institute

Anne L. Levine

Dana-Farber Cancer Institute Harvard Medical School Paul Okunieff, MD

UF Health Cancer Center

Barbara Duffy Stewart, MPH

Association of American Cancer Institutes

Louis M. Weiner, MD

Georgetown Lombardi Comprehensive Cancer Center

George J. Weiner, MD

Holden Comprehensive Cancer Center University of Iowa

Rosalie Wollett, MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

All 2015 AACI/CCAF Annual Meeting sessions will be held in the Grand Ballroom, except where indicated.

Agenda

All sessions held in Grand Ballroom, Ballroom Level unless otherwise noted

Sunday, October 25

11:00 am Registration Begins

Grand Ballroom Foyer, Ballroom Level

11:00 am Exhibits Open

Grand Ballroom Foyer, Ballroom Level

12:30 pm Welcome and AACI Business Meeting

President's Report

Dr. George J. Weiner

Holden Comprehensive Cancer Center University of Iowa

Executive Director's Report

Ms. Barbara Duffy Stewart

Association of American Cancer Institutes

Treasurer's Report

Mr. Jeff Walker

The Ohio State University Comprehensive Cancer Center James Cancer Hospital & Solove Research Institute

Program Chair's Report

Dr. Patrick J. Loehrer

Indiana University Melvin and Bren Simon Cancer Center

CCAF Report

Ms. Anita L. Harrison

Hollings Cancer Center

Medical University of South Carolina

1:15 pm Making the Most of a Life, Interrupted

Ms. Suleika Jaouad

New York Times Emmy® Award Winning Columnist, "Life, Interrupted," and Cancer Survivor

3

Moderator: Ms. Susan Dentzer
Robert Wood Johnson Foundation

2:15 pm Break

2 Program Subject to Change

7:30 pm

Sunday, October 25 continued **Monday, October 26 The Academic Difference: Demonstrating that** 2:30 pm 7:00 am General Breakfast Oriental Ballroom B/C, Ballroom Level **Academic Cancer Centers are More Valuable** than Ever 7:00 am **Exhibits Open** Grand Ballroom Foyer, Ballroom Level Dr. George J. Weiner Holden Comprehensive Cancer Center The Value of a Comparative Oncology Program: 7:00 am University of Iowa **Drugs, Devices, Diagnostics and Development** Oriental Ballroom A. Ballroom Level **Supporting the Academic Mission** 3:00 pm Dr. Michael B. Kastan Moderator: Dr. George J. Weiner Duke Cancer Institute Holden Comprehensive Cancer Center Duke University Medical Center University of Iowa Dr. Rodney Page Mentorship: Nature or Nurture? Pathways or Gateways? Flint Animal Cancer Center Dr. Charles R. Thomas Knight Cancer Institute **Immunology 101: A Primer** 8:00 am Oregon Health & Sciences University Expectations for Immunotherapy in the Next 10 Years: Supporting Clinical Research A Translational Scientist's View Dr. Carolyn D. Britten Moderator and Speaker: Dr. Elizabeth M. Jaffee Hollings Cancer Center Medical University of South Carolina Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine Cost Containment in the Academic Environment **Tumor Immunology 101** Dr. Otis W. Brawley Dr. Louis M. Weiner American Cancer Society Georgetown Lombardi Comprehensive Cancer Center **Sessions End** 4:00 pm Cellular Immunotherapy for Cancer: Infrastructure for Current Approaches and the Future 4:00 pm **CCAF Business Meeting** Dr. Kunle Odunsi (Closed session for members of CCAF) Roswell Park Cancer Institute **3rd Annual AACI Physician Clinical Leadership** 4:00 pm **Initiative Meeting** 9:30 am **Break** Oriental Ballroom A/B. Ballroom Level 6:00 pm -Welcome Reception Grand Ballroom Foyer, Ballroom Level

Program Subject to Change

Monday, October 26 continued

9:45 am

for the Conduct of **Complex Clinical Trials Based on Personalized**

Genomics (concurrent track) Grand Ballroom. Ballroom Level

Moderator: Dr. Randall Holcombe

Mount Sinai Health System Tisch Cancer Institute

Dr. Kirsten Erickson University of Kansas Cancer Center

Ms. Christine Mackay University of Kansas Cancer Center

Mr. Brian Springer Moffitt Cancer Center

Ms. Erin Williams Simmons Cancer Center UT Southwestern Medical Center

Challenges and Solutions Immunology: The Science

(concurrent track) Oriental Ballroom A/B. Ballroom Level

Moderator: Dr. Kunle Odunsi Roswell Park Cancer Institute

Checkpoint Inhibitor Therapy: Current Progress, Future Opportunities

Dr. Michael B. Atkins Georgetown Lombardi Comprehensive Cancer Center

Adoptive T-Cell Therapy: **Targets and Tactics**

Dr. Jim C. Yang National Cancer Institute

Adoptive T-Cell Therapy for Cancer Using Genetically **Engineered Cells** Dr. Crystal L. Mackall

National Cancer Institute

11:00 am AACI Distinguished Scientist Presentation

Targeting PI3K for Cancer Therapy

Dr. Lewis Cantley

Sandra and Edward Meyer Cancer Center Weill Cornell Medical College

6

12:00 pm AACI Awards Luncheon Oriental Ballroom

2015 AACI Distinguished Public Service Award The Honorable Patty Murray (D-WA)

2015 AACI Distinguished Public Service Award The Honorable Kevin Yoder (R-KS)

2015 AACI Champion for Cures Award The Honorable Fred Upton (R-MI)

2015 AACI Champion for Cures Award The Honorable Diana DeGette (D-CO)

Monday, October 26 continued

Fellows' Posters, Exhibits, and Dessert

Grand Ballroom Foyer, Ballroom Level

1:30 pm **NCI Director's Report**

Dr. Douglas R. Lowy National Cancer Institute

2:15 pm

Improving Cancer Care Through Innovative Health IT

Moderator: Dr. Michelle M. Le Beau

The University of Chicago Medicine Comprehensive Cancer Center

Clinical Decision Support in the Era of Genome Informed Cancer Medicine

Dr. Mia Levy

Vanderbilt-Ingram Cancer Center

ORIEN: Data Sharing to Guide Discovery and Delivery of Care

Dr. William S. Dalton

M2Gen

CancerLing: ASCO's Rapid Learning Health System for

Oncology

Dr. Richard L. Schilsky

American Society of Clinical Oncology

3:15 pm

Break

3:30 pm Cancer Research's Other NCI Cancer Center

"Omics" (concurrent track) Oriental Ballroom A/B. Ballroom Level

Moderator: Dr. Theodore S. Lawrence

University of Michigan Comprehensive Cancer Center

The Epigenome: Above the Genome

Dr. Jean-Pierre Issa Fox Chase Cancer Center Temple Health

Support Grant (CCSG): Improving Your Odds

(concurrent track) Grand Ballroom, Ballroom Level

CCSG Site Visits: The Administrative Reviewer's Perspective

Moderator and Speaker: Ms. Anita L. Harrison

Hollings Cancer Center Medical University of South Carolina

7

Concurrent tracks continued on page 8

Program Subject to Change Program Subject to Change

Monday, October 26 continued

Concurrent tracks continued

3:30 pm

Causes and Consequences of microRNA Dysregulation in Cancer

Dr. Carlo M. Croce

The Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute

Metabolomics: Opportunity and Potential

Dr. Chris Beecher

UF Health Cancer Center

We Are Not Alone: The Human Microbiome in Health and Disease

Dr. Claire Fraser

Institute for Genome Sciences University of Maryland School of Medicine

First CCSG Submission -When Are You Ready?

Ms. Sharon Mias

Mount Sinai Health System Tisch Cancer Institute

Comprehensive Status: The UNM Experience

Ms. Melissa Fitzmaurice Neligan

University of New Mexico Comprehensive Cancer Center

CCSG Renewal the Carolina Way

Dr. Chad Ellis

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill

5:00 pm Sessions End

Tuesday, October 27

7:00 am **General Breakfast**

7:00 am **Concurrent Breakfast Roundtable Discussions**

CCSG Site Visits Hillwood Room

Ms. Anita L. Harrison

Hollings Cancer Center Medical University of South Carolina

CCSG Renewal Hillwood Room Dr. Chad Ellis

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill

CCSG Comprehensive Status

Portrait Room

Ms. Melissa Fitzmaurice Neligan

University of New Mexico Comprehensive Cancer Center

CCSG First-Time Application

Freer Room

Ms. Sharon Mias

Mount Sinai Health System Tisch Cancer Institute

Tuesday, October 27 continued

Cancer Survivorship: Up Close and Personal 8:00 am

Moderator: Dr. Patrick J. Loehrer

Indiana University Melvin and Bren Simon Cancer Center

Who Are the Cancer Survivors? Addressing Their Needs and Concerns

Dr. Patricia A. Ganz

Jonsson Comprehensive Cancer Center, UCLA

Resiliency in Diverse Communities: Native American, First Nations, and Indigenous Perspectives

Dr. Rodney C. Haring

Roswell Park Cancer Institute

Survivorship in the Real World Context: Partners and Family

Prof. Matthew J. Loscalzo

City of Hope Comprehensive Cancer Center

Cancer Survivorship: A Physician's Personal Journey

Dr. David H. Johnson

Simmons Cancer Center

UT Southwestern Medical Center

9:00 am **Leveraging Cancer Center Shared Resources**

Moderator: Dr. Edward J. Benz

Dana-Farber Cancer Institute Harvard Medical School

Leveraging Resources and Talent: The San Diego NCI Cancer Centers Council (C3)

Dr. Scott M. Lippman

UC San Diego Moores Cancer Center

Developing a Regional Structural Biology Collaboration Dr. Mair Churchill

University of Colorado

Precision Imaging Metrics: An Infrastructure for Managing Imaging Assessments for Oncology Clinical **Trials Across NCI Cancer Centers**

Dr. Gordon J. Harris

Dana-Farber Cancer Institute Harvard Medical School Massachusetts General Hospital Precision Imaging Metrics

Tuesday, October 27 continued

10:00 am Break

10:15 am NCI Intramural Program Update

Moderator: Dr. George J. Weiner Holden Comprehensive Cancer Center University of Iowa

What is the NCI-Intramural Program?

Dr. Lee J. Helman

Center for Cancer Research, NCI

Collaborative Opportunities with the NCI Intramural Clinical Program

Dr. William L. Dahut

Center for Cancer Research, NCI

The RAS Initiative at Frederick National Lab: Progress and Prospects

Dr. Frank McCormick

Frederick National Laboratory for Cancer Research

11:15 am Update on the NCI Cancer Centers Program

Dr. Henry P. Ciolino *National Cancer Institute*

12:00 pm Adjourn

10

Continuing Medical Education

Joint Providership Statement

Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The American Association for Cancer Research designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above

Learning Objectives

Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program's learning objectives, all attendees should be able to describe and discuss:

- The value of the academic cancer center.
- The role of immunotherapies as promising new treatments for certain cancers.
- Strategies for developing and implementing an immunotherapeutics program at the cancer center.
- The role of signaling pathway phosphoinositide 3-kinase (PI3K) in cancer treatment.
- Best practices for the conduct of clinical research in the cancer center.
- Emerging areas of cancer research which have come into focus as a direct result of the rapid advances in cancer genomics.
- Information technology (IT) platforms currently available to help manage big data with specific models currently available for utilization in the cancer center.
- The National Cancer Institute's newly organized National Clinical Trials Network and how it will serve to facilitate important cancer clinical trials.
- Methods for helping the cancer patient address the full spectrum of challenges from initial diagnosis to prevention and survivorship.
- NCI's programmatic priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to the nation's cancer centers.

Program Subject to Change CME approval granted January 30, 2015 11

Continuing Medical Education

Americans with Disabilities Act

It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvay at 412-605-1476 or attach a note to your registration form.

Faculty Disclosure

It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience

This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI's 95 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care. Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer attend the meeting.

Awardee Profiles

2015 AACI Distinguished Scientist Award



Dr. Lewis CantleySandra and Edward Meyer Cancer Center
Weill Cornell Medical College

A cell biologist and biochemist who serves as The Margaret and Herman Sokol Professor in Oncology Research and director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Lewis Cantley, PhD, has conducted pioneering research resulting in revolutionary treatments for cancer,

diabetes and autoimmune diseases. Among his scientific contributions was the discovery of the phosphoinositide 3-kinase (PI3K) pathway, which enabled a new understanding of the way biochemical signaling pathways control normal cell growth and how they can trigger the development of cancer when they are defective.

Dr. Cantley is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and the author of over 400 original papers and more than 50 book chapters and review articles. He graduated summa cum laude with a BS in chemistry from West Virginia Wesleyan College (1971) and obtained a PhD in biophysical chemistry from Cornell University (1975).

Dr. Cantley conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978. He became a professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992. He became chief of Harvard's new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002. In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and New York-Presbyterian Hospital in 2012.

2015 AACI Distinguished Public Service Award



The Honorable Patty Murray United States Senate

AACI recognizes U.S. Senator Patty Murray (D-WA) with its 2015 Distinguished Public Service Award for her dedicated efforts on behalf of cancer patients and biomedical research.

Sen. Murray has worked to build awareness and increase funding to address the medical needs of women, fighting to ensure that women have access to the care they need, including the promotion of cancer screening and treatment

options. As a member of the Senate Committee on Appropriations, Sen. Murray helped increase funding for cancer screening and early diagnosis. To ensure treatment for low-income women, she helped secure passage of the "Breast and Cervical Cancer Treatment Act of 2000," which provides immediate health care support to low-income women who are diagnosed with breast or cervical cancer.

As Washington state's senior U.S. Senator, Patty Murray has a proven track record of public service spanning more than two decades. Serving as a member of the Senate Democratic leadership since 2007, Sen. Murray has established herself as a tireless and effective leader on education, budget issues, healthcare, women, and veterans' issues.



The Honorable Kevin YoderUnited States House of Representatives

AACI recognizes U.S. Representative Kevin Yoder (R-KS) with its 2015 Distinguished Public Service Award for his dedicated efforts on behalf of cancer patients and biomedical research.

In 2011, Rep. Yoder was sworn in to serve his first term as a Member of the 112th Congress, where he was selected as one of only three freshmen members to serve on the powerful House Committee on Appropriations. In 2015,

he returned to the Committee after being sworn in for his third term in the House of Representatives, serving as the Vice Chairman of the Transportation, Housing and Urban Development Subcommittee.

During his time in Congress, Rep. Yoder has focused on being a leading voice in support of increased federal investment in biomedical research and was a supporter of the University of Kansas Cancer Center receiving its National Cancer Institute designation in 2012. He was recently featured as a thought leader in the Science Coalition's Science 2034 series, and has publicly advocated for increased funding for the National Institutes of Health.

2015 AACI Champion for Cures Award



The Honorable Fred Upton United States House of Representatives

AACI recognizes U.S. Representative Fred Upton (R-MI) with its inaugural Champion for Cures Award for his dedicated efforts on behalf of cancer patients and biomedical research.

In 2010, Rep. Upton was selected by his House colleagues to serve as Chairman of the House Committee on Energy and Commerce. In April 2015, President Obama signed into law

H.R. 2, the Medicare Access and CHIP Reauthorization Act, which permanently fixes the broken Medicare Sustainable Growth Rate, strengthens Medicare in the long-term, extends federal funding for community health centers, and extends the Children's Health Insurance Program (MIChild) which covers nearly 45,000 children in Michigan.

Rep. Fred Upton has led the effort to ensure seniors keep access to their physicians and low-income children keep their insurance coverage. He has long pushed for a greater emphasis on biomedical research to improve the public health. In 2014, along with Rep. Diana DeGette (D-CO), Rep. Upton launched the bipartisan 21st Century Cures initiative. This multi-year effort aims to bring researchers, industry, and patients together to speed the discovery, development, and delivery of life-saving cures. H.R.6 passed the House overwhelmingly by a vote of 344 – 77.



The Honorable Diana DeGetteUnited States House of Representatives

AACI recognizes U.S. Representative Diana DeGette (D-CO) with its inaugural Champion for Cures Award for her dedicated efforts on behalf of cancer patients and biomedical research.

Chief Deputy Whip Diana DeGette is serving her tenth term in Congress as Representative for the First District of Colorado. As a member of the House Committee on Energy

and Commerce, an exclusive congressional committee with vast jurisdiction over health care, trade, business, technology, food safety, and consumer protection, she is one of the leading voices in the health care debate. She also serves as the Ranking Member of the Subcommittee on Oversight and Investigations, which conducts the oversight of, and investigations into, issues falling under the jurisdiction of the full committee.

Ranking Member DeGette, along with her colleague Representative Fred Upton of Michigan, authored House passed, H.R.6, the 21st Century Cures Act, to expedite and improve research and development to the benefit of patients nationwide.

Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- AstraZeneca
- Gilead
- Huron Consulting Group

- Lilly
- Merck
- Pfizer
- Tyler & Company

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Celgene
- Forte Research Systems®
- Genentech

- Gilead
- Lilly
- Merck
- Pfizer
- Takeda Oncology
- Velos

Support as of October 15, 2015

Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Clinical Conductor CTMS

Clinical Conductor is the industry's first collaborative and configurable CTMS for academic and enterprise-level organizations managing or executing complex clinical trials for oncology or other therapeutic areas. Clinical Conductor provides users with the specific financial and protocol management functionality they need to stay compliant and manage dynamic and adaptive clinical trials. Clinical Conductor also allows organizations to effectively collaborate with partners, stick to study timelines and maximize profitability. Used by over 1,800 organizations around the world, Clinical Conductor provides organizations with the tools they need to continue to raise the bar in clinical research.

Complion

Complion, the leading eRegulatory provider for sites, was founded by certified clinical research professionals to empower sites. In collaboration with leading sites and based on best practices, Complion developed Acuvia, a common standard platform for sites to store FDA-compliant electronic regulatory binders and other standardized processes. Complion facilitates the sharing of best practices and educational resources on infoVera.org, a community-led collaborative education initiative, with user-led eRegulatory community work groups.

CURE™

CURE[™], part of the OncLive family, combines science, humanity, and technology to make cancer understandable and navigable for each patient on their personal cancer journey since 2002. CURE[™] is the largest consumer magazine in the United States focused entirely on cancer and connects patients with clinical trials, physicians, and each other. With a print circulation of 289,000, inclusive of individual subscribers, cancer centers, and advocacy groups around the country along with a large digital presence, CURE[™] provides over a million readers with patient video interviews, resource guides for the newly diagnosed, books, online tools, and special events, such as the MPN Heroes[™] and Extraordinary Healer[™] Award for Oncology Nurses.

ECG Management Consultants

ECG is a national consulting firm that is leading healthcare forward, using the knowledge and expertise built over the course of four decades to help clients see clearly where healthcare is going and to navigate toward success. With particular expertise in cancer services strategy and planning, ECG consultants work as trusted, professional partners with academic medical centers, hospitals, health systems, and medical groups across the country. We thrive on developing smart strategies and pragmatic solutions to the critical challenges that will revolutionize the healthcare system. To learn more about our strategy, finance, operations, and technology services, visit us at www.ECGMC.com.

Exhibitors

Forte Research Systems®

Forte Research Systems has been developing software exclusively for clinical research organizations since 2000. Forte's OnCore Enterprise Research system supports efficient research, compliance, data management and budgetary processes at academic medical centers, cancer centers, and healthcare systems across the U.S. Its OnCore user community, Onsemble, connects thousands of researchers throughout the industry.

Opus[™], a new software solution from Forte, streamlines the process of preparing grant applications, renewals, and progress reports by serving as a repository of all research activities and accomplishments. Opus helps research organizations complete grant submission prep work in a fraction of the time it previously took.

iLab Solutions, LLC

iLab Solutions is the global leader in providing web-based core facility management services to academic research institutions. The functionality includes request management, equipment reservation and usage tracking, project tracking, billing and invoicing, and reporting. iLab has extensive experience providing enterprise-level solutions at major research institutions, including integrations with institutional financial systems (e.g., SAP, Oracle, PeopleSoft, Lawson, Banner, IFAS, etc.) and identity management systems (e.g., Active Directory, LDAP, Shibboleth, etc.). iLab's dedicated implementation team and full customer support result in high adoption rates. Core facilities across 125 institutions in North America, Europe, and the Asia-Pacific region rely on iLab, including universities, hospitals, independent institutes, and government labs.

Intellisphere

Intellisphere is a leading provider of healthcare publishing, research, information, and education for the medical industry. Our company serves the needs of hundreds of thousands of general practitioners, specialists, patients, nurses, pharmacists, and managed care professionals through an extensive suite of magazines, journals, e-mail databases, websites, events, and personal meetings. We strive to inform and educate oncology professionals and patients with the latest clinically relevant news and insights through our OncLive® and CURE Media Group publications and website. Through our Strategic Alliance Partnership program, we are able to promote the research innovation and outreach programs of the leading cancer centers and oncology nursing programs across the country. The partnerships provide our audience with direct access to important research, clinical trial initiatives, and clinical practice news that are ongoing at these institutions.

Precision Imaging Metrics

Precision Imaging Metrics helps cancer centers across the country produce higher-quality and timelier imaging data, enhancing clinical trials and patient care. In 2004, Drs. Gordon Harris and Annick Van den Abbeele founded the Tumor Imaging Metrics Core (TIMC) at the Dana Farber/Harvard Cancer Center (DF/HCC). Since its inception, TIMC has analyzed over 50,000 scans for over 1000 clinical trials. This vast experience is the foundation on which Precision Imaging Metrics — and its flagship Metrics Manager application — has been built. The Metrics Manager application is currently in use by DF/HCC, Yale Cancer Center, Fred Hutchinson-University of Washington Cancer Center, and the Huntsman Cancer Institute at the University of Utah.

Stratocore

Stratocore's PPMS software has been the gold standard platform for scientific core facility management since 2003. Designed to scale, PPMS evolves from a single lab to an entire university network with ease. Stratocore streamlines the organization of services, invoicing, reservations, assistance, trainings, maintenance, technical incidents, project and publication management and reporting. With the expertise of Stratocore's support team, we ensure rapid deployment and guarantee continued responsive, knowledgeable, efficient service. We provide integration with all major financial ERP systems as well as authentication management systems and corporate logo and identity integration. PPMS produces auditable, compliant and fully integrated ERP data management for Research Scientists & Administrators. Developed by practicing scientists, and continuously refined for over 10 years through user feedback, PPMS remains simple and user friendly while offering powerful, flexible control for higher efficiency and research productivity. With over one hundred top tier clients worldwide, and thousands of users trusting us every day with the management of their most valuable research assets, the Stratocore Team is proud to serve the global research community.

Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Shareholder, SB, Speakers' Bureau, H, Honoraria, O, Other.

Last Name	First Name	Affiliation	Relationships	Туре	Role
Atkins	Michael	Georgetown Lombardi Comprehensive Cancer Center	BMS, Merck, Pfizer, Genentech, Novartis	A	Speaker
Beecher	Christopher	University of Florida	IROA Technology	A,E	Speaker
Benz	Edward	Dana-Farber Cancer Institute	No Relationships		Speaker
Bertram	Michael	University of Alabama at Birmingham	No Relationships		Program Committee
Brawley	Otis	American Cancer Society	No Relationships		Speaker
Britten	Carolyn	Medical University of South Carolina Hollings Cancer Center	Pfizer, Novartis, Lilly, EMD Serono, Bayer, Plexxikon, Incyte, Boston Biomedical, AstraZeneca, Apogee	G	Speaker
Cantley	Lewis	Weill Cornell Medical College, New York- Presbyterian Hospital	Novartis, Pfizer, Genentech, BMS, Agios	A,O,C,G	Speaker
Churchill	Mair	University of Colorado	No Relationships		Speaker
Ciolino	Henry	National Cancer Institute	No Relationships		Speaker
Croce	Carlo	Ohio State University Comprehensive Cancer Center	No Relationships		Speaker
Dahut	William	National Cancer Institute	No Relationships		Speaker
Dalton	William	Moffitt Cancer Center & Research Institute	M2Gen	E,G	Speaker
Dentzer	Susan	Robert Wood Johnson Foundation	No Relationships		Speaker
Ellis	Chad	UNC Lineberger Comprehensive Cancer Center	No Relationships		Speaker
Fitzmaurice Neligan	Melissa	UNM Comprehensive Cancer Center	No Relationships		Speaker
Fraser	Claire	Institute for Genome Sciences, University of Maryland School of Medicine	No Relationships		Speaker
Ganz	Patricia	UCLA Jonsson Comprehensive Cancer Center	No Relationships		Speaker
Haring	Rodney	Roswell Park Cancer Institute	No Relationships		Speaker
Harris	Gordon	Massachusetts General Hospital	Fovia, Inc.	Α	Speaker
Harrison	Anita	Medical University of South Carolina	No Relationships		Program Committee, Speaker
Helman	Lee	National Cancer Institute	No Relationships		Speaker
Issa	Jean-Pierre	Fels Institute for Cancer Research & Molecular Biology	Astex, Bl. Janssen, Teva	C,G,H	Speaker
Jaffee	Elizabeth	Johns Hopkins Kimmel Comprehensive Cancer Center	Roche, Aduro Biotech, BMS	G,0	Speaker
Jaouad	Suleika	Self-Employed	No Relationships		Speaker
Johnson	Candace	Roswell Park Cancer Institute	No Relationships		Program Committee
Johnson	David	UT Southwestern Medical School	No Relationships		Speaker
Kastan	Michael	Duke Cancer Institute	No Relationships		Speaker
Lawrence	Theodore	University of Michigan	No Relationships No Relationships		Speaker
Le Beau	Michelle	University of Chicago Medicine Comprehensive Cancer Center	No Relationships		Speaker
Levine	Anne	Dana-Farber Cancer Institute	No Relationships		Program Committee
Levy	Mia	Vanderbilt University	Personalis, GenomOncology	G,C,S,A	Speaker
Lippman	Scott	UCSD Moores Cancer Center	Biological Dynamics, Human Longevity, Inc	S,A	Speaker
Loehrer	Patrick	Indiana University Melvin and Bren Simon Cancer Center	Novartis, Pfizer	G	Program Committee, Speaker
Loscalzo	Matthew	City of Hope	SupportScreen, Novartis	O,SB	Speaker
Lowy	Douglas	National Cancer Institute	Merck, GlaxoSmithKline, Indian Immunologicals	0,50	Speaker
Mackall	Crystal	National Cancer Institute National Cancer Institute	Juno Therapeutics	G, 0	Speaker
McCormick	Frank	UCSF Helen Diller Family Comprehensive Cancer Center	K-Gen, Leidos	C,S	Speaker
Mias	Sharon	Tisch Cancer Institute at Mount Sinai	No Relationships	C,3	Speaker
Odunsi	Kunle	Roswell Park Cancer Institute	No Relationships No Relationships		Speaker
Okunieff	Paul	University of Florida Shands Cancer Center	BrainLAB	С	Program Committee
	Rodnev	Colorado State University	No Relationships	C	Speaker
Page	Richard	,			-1
Schilsky		American Society of Clinical Oncology Association of American Cancer Institutes	No Relationships		Speaker
Stewart	Barbara Charles	OHSU Knight Cancer Institutes OHSU Knight Cancer Institute	No Relationships No Relationships		Program Committee, Speaker Speaker
Thomas		3	NO REIGIONSTIPS	466110	11.11
Weiner	Louis	Georgetown Lombardi Comprehensive Cancer Center	Celldex Pharmaceuticals, Jounce Pharmaceuticals, Merrimack Pharmaceuticals, Targeted Diagnostics and Therapeutics, Inc., AbbVie, Novartis, Clinical Options, Cytomx, Immunome, Progress, Symphogen, Immunovative Therapies, Ltd., Genentech, Merck, Novartis	A,S,C,H,O	Program Committee, Speaker
Weiner	George	University of Iowa Holden Comprehensive Cancer Center	No Relationships		Program Committee, Speaker
Wollett	Rosalie	Johns Hopkins University	No Relationships		Program Committee
Yang	James	National Cancer Institute	No Relationships		Speaker